The brief
- Aug 2026: its cancer vaccine plus Keytruda met Phase 3 goals, cutting melanoma return and spread after surgery.
- Revenue fell sharply after the pandemic, forcing cost cuts while it builds new vaccines and cancer drugs.
Programs
Moderna, two programs
Updated 19 Aug 2026Intismeran autogene (mRNA-4157/V940)Each patient's tumor is read, software picks up to 34 targets unique to it, and a custom mRNA vaccine is made. Given with Keytruda, it trains the immune system to attack that cancer.DeployNextFiling with regulatorsUpdated 19 Aug 2026View program →Respiratory vaccinesmRNA vaccines that teach cells to show a piece of a virus: the original Spikevax, the lower-dose mNEXSPIKE and the RSV vaccine mRESVIA.ScalingUpdated 31 May 2024View program →
Research · Proto · Pilot · Deploy · Scaling
Company & funding
- Listed
- MRNA (opens google.com)NASDAQ
- HQ
- US
- Founded
- 2010
Partners & customers
- Partner
Co-develops intismeran autogene with Keytruda (pembrolizumab).